- The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc's REGN REGEN-COV.
- The casirivimab and imdevimab antibody cocktail (Ronapreve) was backed by the CHMP for treating adults and children over 12 with COVID-19 who do not require oxygen support and are at high risk of severe disease.
- Related Link: Regeneron-Roche's COVID-19 Treatment Shows Long Term Benefit After Single Dose.
- Regeneron is collaborating with Roche Holdings AG RHHBY, primarily responsible for development and distribution outside the U.S.
- Price Action: REGN shares are up 0.77% at $627, RHHBY stock is up 0.18% at $50.32 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
